Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Patient Resources
Clinical Trial Listings
What are Clinical Trials?
Become a Clinical Trial Volunteer
Useful Resources
FDA Approved Drugs
Professional Resources
Research Center Profiles
Market Research
Benchmark Reports
FDA Approved Drugs
Training Guides
Books
eLearning
Events
Newsletters
White Papers
SOPs
White Papers
Clinical Trial Listings
Advertise
Sign In
Create Account
Sign Out
My Account
Home
» Crucial CTA Clauses Must Be Phrased Carefully to Avoid Delays
Looking to read the full article? Subscribe today!
Crucial CTA Clauses Must Be Phrased Carefully to Avoid Delays
December 1, 2022
James Miessler
The language in clinical trial agreements (CTA) must be very specific to avoid legal problems during the trial, but certain terms have the potential, if not handled correctly, to derail the negotiation process before the trial gets off the ground.
Upcoming Events
07
May
Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials
14
May
2024 Avoca Quality Consortium Summit
Featured Products
Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs
Best Practices for Clinical Trial Site Management
Featured Stories
Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials
Ask the Experts: Applying Quality by Design to Protocols
Clinical Trials Need Greater Representation of Obese Patients, Experts Say
FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
The information you need to adapt your monitoring plan to changing times.
Learn More Here